We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

This study is currently recruiting participants.
Verified August 2017 by Xcovery Holding Company, LLC
Sponsor:
ClinicalTrials.gov Identifier:
NCT01625234
First Posted: June 21, 2012
Last Update Posted: August 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Xcovery Holding Company, LLC
  Purpose
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans (the maximum tolerated dose). Once the recommended Phase 2 dose has been determined, an expansion phase will assess the preliminary anti-tumor activity of X-396 in ALK-positive non-small cell lung cancer. The study will also provide early information on how the body handles the drug (pharmacokinetics) and on the efficacy of X-396.

Condition Intervention Phase
Advanced Solid Tumors Non-small Cell Lung Cancer Drug: X-396 (ensartinib) Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Xcovery Holding Company, LLC:

Primary Outcome Measures:
  • Maximum Tolerated Dose [ Time Frame: 12 months ]
    To evaluate the safety/tolerability of X-396 (ensartinib) and determine the maximum tolerated dose (MTD) of X-396 as a single agent.


Secondary Outcome Measures:
  • Plasma Concentrations (Cmax, Tmax, AUC, half-life) [ Time Frame: 18 months ]
    To characterize the preliminary pharmacokinetics including Cmax, Tmax, AUC, half-life of X-396 given as a single agent

  • Preliminary Tumor Response [ Time Frame: 18 months ]
    To explore the preliminary clinical tumor response after treatment with X-396 (ensartinib) given as a single agent.


Estimated Enrollment: 150
Study Start Date: June 2012
Estimated Study Completion Date: November 2020
Estimated Primary Completion Date: November 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: X-396 (ensartinib)
Dose escalation starting at 25 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
Drug: X-396 (ensartinib)
Oral, ALK inhibitor

Detailed Description:
This is the first study of X-396 (ensartinib) in humans and the investigational drug will be given as a once or twice daily oral dose in 28 day cycles until there is disease progression or unacceptable safety issues. X-396 will be given to small groups of patients (1 - 6) at each dose level and the patients will be observed to see if there are any adverse safety effects. As long as there are no unacceptable safety issues after 28 days, the dose of X-396 will be increased for the next group of patients. This process will continue until the maximum tolerated dose (MTD) of X-396 is reached. Once the MTD is reached, up to 60 additional patients will also be given X-396 to further determine the activity of X-396 in patients with ALK-positive non-small cell lung cancer. These additional patients will be enrolled in the following 5 expansion cohorts: ALK TKI-naïve patients, patients that progressed on crizotinib, patients that progressed on one or more 2nd generation ALK TKIs (patients may or may not have also received prior crizotinib), patients with asymptomatic CNS metastases, and patients with leptomeningeal disease.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy. Patients may have received prior crizotinib and/or second generation ALK TKIs (patient must have progressed on alectinib).

    -For the expanded cohort portion of the study, patients must have NSCLC with ALK genomic alterations positive by FISH or IHC testing done centrally; however, patients will be allowed to enroll based on local ALK FISH or IHC results.

  2. Eastern Cooperative Group ECOG) Performance Status score of 0 or 1.
  3. Ability to swallow and retain oral medication.
  4. Adequate organ system function.
  5. Patients with treated or untreated asymptomatic CNS metastases may be allowed to enroll.
  6. Male patients willing to use adequate contraceptive measures.
  7. Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures.
  8. Patients must be ≥ 18 years of age.
  9. Patients must have measurable or evaluable disease for the dose escalation portion of the study and measurable disease for the expanded cohort portion of the study (except for patients in the CNS metastases and leptomeningeal cohorts).
  10. Patients entering this study will be asked to provide tissue for correlative testing (if available).
  11. Willingness and ability to comply with the trial and follow-up procedures.
  12. Ability to understand the nature of this trial and give written informed consent.

Exclusion Criteria:

  1. Patients currently receiving cancer therapy.
  2. Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of X-396.
  3. Any major surgery, radiotherapy, or immunotherapy within the last 21 days. Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks.
  4. Prior stem cell transplant.
  5. Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to X-396 (e.g., crizotinib) or to the active ingredient of X-396.
  6. Patients with primary CNS tumors are ineligible.
  7. Concomitant use of herbal medications at least 7 days prior to the first dose of study drug and throughout participation in the trial.
  8. Females who are pregnant or breastfeeding.
  9. Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-396.
  10. Clinically significant cardiovascular disease.
  11. Patients who are immunosuppressed (including known HIV infection), have a serious active infection at the time of treatment, have known hepatitis C, or have any serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
  12. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
  13. Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol or would impart excessive risk associated with study participation that would make it inappropriate for the patient to be enrolled.
  14. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01625234


  Hide Study Locations
Locations
United States, California
City of Hope National Med Ctr Recruiting
Duarte, California, United States, 91010
Contact: Michael Donor    626-256-4673 ext 80749    mdonor@coh.org   
Principal Investigator: Karen Reckamp, M.D.         
UCSD Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Klarissa Son    858-822-5369    kson@ucsd.edu   
Principal Investigator: Sandip Patel, M.D.         
Loma Linda University Cancer Center Recruiting
Loma Linda, California, United States, 92354
Contact: Tiffany Sanchez    909-558-4050      
Principal Investigator: Hamid Mirshahidi, MD         
University of Southern California Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Gina Tse    323-865-3962    tse_g@med.usc.edu   
Principal Investigator: Barbara Gitlitz, MD         
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Richard Quick    650-723-2983    richardq@stanford.edu   
Principal Investigator: Heather Wakelee, M.D.         
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Heloise Borges    813-745-6141    heloise.borges@moffitt.org   
Principal Investigator: Alberto Chiappori, MD         
United States, Maryland
Walter Reed National Military Medical Center Recruiting
Bethesda, Maryland, United States, 20889
Contact: Virginia (Ginger) Schmidt    301-295-6814    Virginia.f.schmidt3.ctr@mail.mil   
Principal Investigator: Christina Brzezniak, M.D.         
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Bryan Marion    617-632-3383    mailto:bryan_marion@dfci.harvard.edu   
Principal Investigator: Geoffrey Oxnard         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Melissa Meredith, MS, CCRP    314-362-4140    mmeredith@dom.wustl.edu   
Contact: Ian McGowan    314-747-7569    imcgowan@dom.wustl.edu   
Principal Investigator: Saiama N Waqar, MD         
United States, New York
New York University Langone Medical Center Recruiting
New York, New York, United States, 10016
Contact: Taylor Mazac    929-455-2435    taylor.mazac@nyumc.org   
Principal Investigator: Leena Gandhi         
Stony Brook University Cancer Center Recruiting
Stony Brook, New York, United States, 11794
Contact: Kim Lyktey    631-638-1000    Kim.Lyktey@stonybrookmedicine.edu   
Principal Investigator: Roger Keresztes, MD         
Montefiore Medical Center Recruiting
The Bronx, New York, United States, 10461
Contact: Danny Paucar    718-405-8539    dpaucar@montefiore.org   
Principal Investigator: Haiying Cheng, MD         
United States, Ohio
Ohio State University Withdrawn
Columbus, Ohio, United States, 43210
United States, Oregon
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Brenda Fisher    503-215-2613    brenda.fisher@providence.org   
Principal Investigator: Rachel Sanborn, MD         
United States, Pennsylvania
Penn State Hershey Medical Center Withdrawn
Hershey, Pennsylvania, United States, 17033
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Lindsay Hopkins    215-214-3789    Lindsay.Hopkins@fccc.edu   
Principal Investigator: Jessica Bauman         
United States, South Carolina
Medical University of South Carolina Withdrawn
Charleston, South Carolina, United States, 29425
United States, Tennessee
Sarah Cannon Research Institute Completed
Nashville, Tennessee, United States, 37203
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37240
Contact: Rhonda Combs    800-811-8480    cip@vanderbilt.edu   
Principal Investigator: Leora Horn, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: George Blumenschein    855-873-4321      
Principal Investigator: George Blumenschein, MD         
United States, Virginia
University of Virginia Cancer Center Recruiting
Charlottesville, Virginia, United States, 22903
Contact: Maria Davenport    434-297-4110 ext 4608    mbd5z@hscmail.mcc.virginia.edu   
Principal Investigator: Richard Hall, MD         
United States, West Virginia
West Virginia University Hospital Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Carla Ross    304-581-1158    cjross@hsc.wvu.edu   
Principal Investigator: Patrick C Ma, MD, MSc         
United States, Wisconsin
University of Wisconsin Carbone Cancer Ctr Recruiting
Madison, Wisconsin, United States, 53792
Contact: Tessa Kroeninger    608-262-5706    kroeninger@wisc.edu   
Contact: Hilary R Hernan       hrhernan@uwcarbone.wisc.edu   
Principal Investigator: Ticiana Leal, M.D.         
Sponsors and Collaborators
Xcovery Holding Company, LLC
  More Information

Publications:
Responsible Party: Xcovery Holding Company, LLC
ClinicalTrials.gov Identifier: NCT01625234     History of Changes
Other Study ID Numbers: X396-CLI-101
First Submitted: June 15, 2012
First Posted: June 21, 2012
Last Update Posted: August 18, 2017
Last Verified: August 2017

Keywords provided by Xcovery Holding Company, LLC:
Cancer
Tumors
ALK
NSCLC
Advanced Malignancies
Carcinoma, Non-Small-Cell Lung
Inflammatory Myofibroblastic Tumors

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms